Free tool
FAERS Monitor: Cimzia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125160 or its brand name (Cimzia, Certolizumab Pegol). Reports on generic versions are filed under their own applications.
Reports
119,210
Serious
76,429
64% of reports
Hospitalization
21,861
Death reported
6,869
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective27,487
- rheumatoid arthritis20,222
- pain16,271
- fatigue13,878
- off label use11,976
- rash11,259
- arthralgia11,196
- alopecia10,275
- maternal exposure during pregnancy9,987
- joint swelling9,984
- abdominal discomfort9,709
- systemic lupus erythematosus9,289
- swelling8,877
- pemphigus8,861
- drug intolerance8,813
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 29 |
| 2009 | 2,235 |
| 2010 | 3,589 |
| 2011 | 3,495 |
| 2012 | 1,594 |
| 2013 | 1,751 |
| 2014 | 1,658 |
| 2015 | 2,889 |
| 2016 | 5,758 |
| 2017 | 4,121 |
| 2018 | 5,052 |
| 2019 | 12,587 |
| 2020 | 10,671 |
| 2021 | 10,545 |
| 2022 | 11,785 |
| 2023 | 10,486 |
| 2024 | 12,714 |
| 2025 | 12,095 |
| 2026 | 6,151 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,934,949 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 8,861 | 426.0 | 410.1 | 1,097,226 |
| systemic lupus erythematosusSignal | 9,289 | 62.2 | 60.8 | 413,537 |
| rheumatoid arthritisSignal | 20,222 | 38.0 | 37.5 | 602,323 |
| maternal exposure during pregnancySignal | 9,987 | 22.1 | 21.7 | 179,737 |
| swellingSignal | 8,877 | 18.4 | 18.0 | 132,657 |
| drug intoleranceSignal | 8,813 | 17.6 | 17.2 | 126,051 |
| joint swellingSignal | 9,984 | 15.8 | 15.5 | 127,854 |
| abdominal discomfortSignal | 9,709 | 10.8 | 10.6 | 81,781 |
| alopeciaSignal | 10,275 | 9.7 | 9.5 | 76,551 |
| arthralgiaSignal | 11,196 | 4.9 | 4.8 | 34,014 |
| painSignal | 16,271 | 4.8 | 4.7 | 48,667 |
| rashSignal | 11,259 | 4.7 | 4.6 | 32,102 |
| drug ineffectiveSignal | 27,487 | 3.7 | 3.7 | 57,551 |
| fatigueSignal | 13,878 | 3.2 | 3.1 | 21,202 |
| off label useSignal | 11,976 | 2.4 | 2.4 | 10,398 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.